<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1018155973627201&amp;ev=PageView&amp;noscript=1"> SIGN Migraine Guidelines 2026: What the Updated UK Recommendations Mean for You | TribElle
Skip to content
Discover the updated SIGN migraine guidelines for 2026, including new recommendations on migraine treatment, prevention, medication use, and holistic migraine management in the UK.
Migraine Pain Management

Migraine Guidelines 2026 UK | Updated SIGN Migraine Treatment Advice

TribeTeam
TribeTeam

Reviewed by Julie Boora, Superintendent Pharmacist, TribElle Health Ltd (GPhC Reg. 9012688)

10M+ UK migraine sufferers   #3 Most disabling condition worldwide   2026 Updated SIGN guidance
 

Migraines affect more than 10 million people across the UK and remain one of the most common neurological conditions worldwide. For many individuals, migraine attacks can significantly impact work, sleep, mental wellbeing, family life, and overall quality of life.

The updated SIGN migraine guidance for 2026 introduces important recommendations designed to improve migraine diagnosis, treatment, prevention, and long-term management.

The latest guidance reflects a growing understanding that migraine is not "just a headache" — it is a complex neurological condition requiring personalised, evidence-based care.

Quick answer

The primary goal of the new SIGN migraine guidance is to improve migraine outcomes through earlier diagnosis, evidence-based treatment, preventative care, and better long-term management strategies.

 

What are the updated SIGN migraine guidelines?

The Scottish Intercollegiate Guidelines Network (SIGN) updated its migraine recommendations to reflect the latest clinical evidence surrounding:

Acute treatment Preventative therapies Medication overuse Lifestyle management Patient education Personalised care planning
 

Understanding migraine: more than a headache

Migraine is a neurological condition that can cause a wide range of symptoms. Attacks may last from several hours to multiple days and vary significantly between individuals.

Common symptoms

Severe throbbing head pain
Sensitivity to light and sound
Nausea and vomiting
Visual disturbances or aura

Also common

Fatigue
Dizziness
Cognitive difficulties
Brain fog

The updated SIGN guidance reinforces the importance of recognising migraine as a serious health condition that often requires ongoing management rather than occasional symptom treatment.

 

Key changes in the 2026 migraine guidance

The updated recommendations place greater emphasis on three areas:

1

Early and accurate diagnosis

Many migraine sufferers experience delayed diagnosis or confusion with other headache disorders. The guidance encourages clinicians to improve diagnostic accuracy by identifying common migraine patterns, triggers, and associated neurological symptoms earlier.

2

Preventative migraine treatment

Preventative therapies are increasingly recommended for people experiencing frequent or disabling migraine attacks. The guidance highlights the importance of considering preventative treatment when migraines significantly affect:

Daily function, employment, and education
Sleep and mental wellbeing
3

Avoiding medication overuse headaches

Frequent use of painkillers can sometimes worsen headaches over time. The updated recommendations stress the importance of reviewing medication use carefully to reduce the risk of medication overuse headaches, which can become difficult to manage long term.

 

Recommended migraine treatments in 2026

The SIGN update supports a combination of medical and non-medical migraine management approaches.

Acute treatments

For immediate symptom relief, clinicians may consider:

Triptans
Anti-inflammatory medications
Antiemetics for nausea
Combination therapies where appropriate

Preventative treatment

Preventative medication may help reduce:

Migraine frequency
Attack severity and duration
Reliance on acute medication
 

Lifestyle and trigger management

The guidance also highlights the importance of identifying and managing common migraine triggers:

😰 Stress 😴 Sleep disruption 💊 Hormonal changes 💧 Dehydration 🍷 Certain foods or alcohol 📱 Excessive screen exposure

Keeping a migraine diary may help you identify patterns and improve self-management — and is something many clinicians now recommend as part of a personalised care plan.

 

The importance of holistic migraine care

One of the most important themes in the updated guidance is the move toward holistic, patient-centred care. Migraine is closely linked with broader health factors:

🧠 Mental wellbeingAnxiety and stress are both triggers and consequences of chronic migraine
😴 Sleep qualityPoor sleep increases attack frequency and severity
💊 Hormonal healthHormonal changes are a significant migraine trigger in women
🥗 Diet and hydrationDehydration and dietary triggers are among the most common and manageable factors
 

Common symptoms you should not ignore

The updated guidance encourages patients to seek professional support if they experience:

Seek professional support if you notice:

Frequent migraine attacks
Worsening headache severity
Neurological symptoms
Sudden changes in headache patterns
Significant impact on daily life
Medication becoming less effective
 

How TribElle supports modern migraine management

As migraine care evolves, TribElle supports a modern approach that reflects the latest guidance:

🎯 Patient-centred wellbeingPersonalised care that treats the whole person, not just the headache
📋 Evidence-informed careTreatments aligned with the latest SIGN guidance and clinical evidence
🔄 Long-term managementSupport strategies focused on reducing frequency and severity over time
📚 Education and self-managementHelping you understand your triggers and take control of your care
 

Where Can You Get Migraine Treatment in the UK?

If you've been diagnosed with migraine, there are several ways to access treatment depending on the severity and frequency of your symptoms.

For occasional migraines, many UK online pharmacies, including TribElle, can assess your suitability for acute prescription treatments such as triptans following an online consultation with a UK-registered prescriber.

However, if you're experiencing frequent or disabling migraines, you may benefit from assessment by a specialist headache clinic or neurologist.

What Is Chronic Migraine?

According to UK clinical guidance, chronic migraine is defined as experiencing:

  • 15 or more headache days each month, and
  • At least 8 of those days have migraine features

People living with chronic migraine often require preventive treatment rather than medication taken only during an attack. Specialist assessment can help determine which treatment options may be most appropriate.

Treatments Available for Chronic Migraine

If your migraines occur frequently or significantly affect your quality of life, a specialist may recommend preventive treatment to reduce the number and severity of migraine attacks.

Depending on your medical history and previous treatments, options may include:

Oral Preventive Medicines

Common first-line preventive medicines include:

  • Propranolol
  • Candesartan
  • Topiramate
  • Amitriptyline

These medicines are taken regularly to help reduce migraine frequency rather than treating an individual attack.

Botulinum Toxin (Botox®)

Botulinum toxin may be recommended for adults with chronic migraine who have not responded to, or cannot tolerate, at least three preventive medicines. Treatment is administered by trained specialists and is usually repeated approximately every 12 weeks.

CGRP-Targeted Treatments

Calcitonin Gene-Related Peptide (CGRP) therapies have transformed migraine prevention for many people living with chronic migraine.

Depending on clinical eligibility, these treatments may include:

  • Erenumab
  • Fremanezumab
  • Galcanezumab
  • Eptinezumab

These medicines work by blocking the CGRP pathway involved in migraine attacks and are typically prescribed by specialist headache services.

Atogepant

Atogepant is an oral CGRP receptor antagonist used for migraine prevention in eligible patients and may be prescribed in accordance with current NICE guidance.

NHS or Private Migraine Treatment?

NHS Care

People who meet NICE eligibility criteria may be referred by their GP to a neurologist or specialist headache clinic for advanced migraine treatments such as Botox® or CGRP-targeted medicines.

Waiting times vary across the UK depending on local services.

Private Care

Private headache clinics and consultant neurologists may offer earlier access to specialist assessment and advanced migraine treatments where clinically appropriate.

Private treatment may be suitable for people seeking faster access to specialist advice or those wishing to explore additional treatment options.

How TribElle Can Help

TribElle is a UK-registered online pharmacy specialising in women's health. While we do not currently provide specialist chronic migraine management, we support women experiencing episodic migraine by offering convenient online consultations for suitable acute migraine treatments, alongside trusted clinical advice and educational resources.

If your migraine symptoms are becoming more frequent, your medication is no longer effective, or you're experiencing headaches on 15 or more days each month, we recommend speaking to your GP or requesting referral to a specialist headache service for further assessment.

References

  1. National Migraine Centre. Migraine treatment and specialist services.
  2. NICE. Headaches in over 12s: diagnosis and management (CG150).
  3. International Headache Society. International Classification of Headache Disorders, 3rd edition (ICHD-3).
  4. NICE Technology Appraisal: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine.
  5. NICE Technology Appraisal: Atogepant for preventing episodic migraine.
  6. NICE. Headaches in over 12s: diagnosis and management (CG150).
  7. British Association for the Study of Headache (BASH). National migraine management guidance.

Frequently asked questions

 

Bottom line

The updated SIGN migraine guidelines for 2026 represent an important step forward in improving migraine care across the UK. By focusing on earlier diagnosis, preventative treatment, safer medication use, and holistic support, the guidance encourages a more effective and compassionate approach to migraine management.

For patients living with migraines, this means greater recognition of the condition's impact and more personalised support strategies designed to improve long-term quality of life.

Managing migraines starts with having the right products to hand. Here's what we stock at TribElle.

Ready to support your migraine management?

Nurofen 200mg Caplets £2.77
4Head Migraine QuickStrips £5.00

© TribElle Health Ltd · GPhC Registration 9012688 · tribelle.co.uk · This content is for informational purposes only. Always consult a qualified healthcare professional.

🧠

Explore treatments

Explore treatment types that might suit you

Hormone-aware migraine care and prescription options, reviewed by clinicians.

See migraine treatments →

Join the conversation

You don't have to go through this alone

👥

Hormonal Migraine Support UK

A community for women navigating hormone-related migraines

Join group
💛

TribElle Weight Management Support

Connect with other women on their weight management journey

Join group

Share this post